Employers Holdings Inc. Takes $221,000 Position in Bristol-Myers Squibb Co (NYSE:BMY)

Employers Holdings Inc. purchased a new stake in shares of Bristol-Myers Squibb Co (NYSE:BMY) in the second quarter, according to its most recent 13F filing with the SEC. The fund purchased 4,870 shares of the biopharmaceutical company’s stock, valued at approximately $221,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. FMR LLC grew its position in shares of Bristol-Myers Squibb by 313.9% during the 1st quarter. FMR LLC now owns 40,851,887 shares of the biopharmaceutical company’s stock valued at $1,949,043,000 after purchasing an additional 30,981,844 shares in the last quarter. Janus Henderson Group PLC grew its position in shares of Bristol-Myers Squibb by 75.7% during the 2nd quarter. Janus Henderson Group PLC now owns 16,156,559 shares of the biopharmaceutical company’s stock valued at $732,691,000 after purchasing an additional 6,960,047 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. grew its position in shares of Bristol-Myers Squibb by 1.1% during the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 7,251,891 shares of the biopharmaceutical company’s stock valued at $328,873,000 after purchasing an additional 78,260 shares in the last quarter. Nordea Investment Management AB lifted its holdings in shares of Bristol-Myers Squibb by 380.2% during the 1st quarter. Nordea Investment Management AB now owns 6,252,847 shares of the biopharmaceutical company’s stock worth $298,324,000 after acquiring an additional 4,950,748 shares during the last quarter. Finally, California Public Employees Retirement System lifted its holdings in shares of Bristol-Myers Squibb by 14.3% during the 1st quarter. California Public Employees Retirement System now owns 5,118,016 shares of the biopharmaceutical company’s stock worth $244,181,000 after acquiring an additional 642,267 shares during the last quarter. Hedge funds and other institutional investors own 77.37% of the company’s stock.

Shares of NYSE BMY traded up $1.23 during mid-day trading on Friday, reaching $46.98. 9,425,900 shares of the company were exchanged, compared to its average volume of 15,176,157. Bristol-Myers Squibb Co has a 52 week low of $42.48 and a 52 week high of $63.69. The company has a quick ratio of 3.75, a current ratio of 3.88 and a debt-to-equity ratio of 1.51. The stock has a market capitalization of $76.85 billion, a PE ratio of 11.80, a PEG ratio of 2.26 and a beta of 0.73. The company’s 50 day moving average price is $45.33 and its 200 day moving average price is $47.45.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, July 25th. The biopharmaceutical company reported $1.18 earnings per share for the quarter, topping the consensus estimate of $1.06 by $0.12. The business had revenue of $6.27 billion during the quarter, compared to the consensus estimate of $6.10 billion. Bristol-Myers Squibb had a net margin of 26.14% and a return on equity of 47.63%. The firm’s revenue for the quarter was up 10.0% on a year-over-year basis. During the same period in the previous year, the firm posted $1.01 earnings per share. On average, sell-side analysts predict that Bristol-Myers Squibb Co will post 4.26 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which was paid on Thursday, August 1st. Shareholders of record on Friday, July 5th were paid a $0.41 dividend. This represents a $1.64 annualized dividend and a yield of 3.49%. The ex-dividend date of this dividend was Wednesday, July 3rd. Bristol-Myers Squibb’s dividend payout ratio is presently 41.21%.

A number of research firms have recently issued reports on BMY. JPMorgan Chase & Co. began coverage on shares of Bristol-Myers Squibb in a report on Friday, May 3rd. They set an “overweight” rating and a $62.00 price objective for the company. Argus downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $46.36 price objective for the company. in a report on Monday, May 20th. Atlantic Securities raised shares of Bristol-Myers Squibb from a “neutral” rating to an “overweight” rating and set a $63.00 price objective for the company in a report on Wednesday. Barclays raised shares of Bristol-Myers Squibb from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $53.00 to $55.00 in a report on Friday, May 3rd. Finally, Goldman Sachs Group began coverage on shares of Bristol-Myers Squibb in a report on Tuesday, May 28th. They set a “buy” rating and a $54.00 price objective for the company. One research analyst has rated the stock with a sell rating, eight have given a hold rating and nine have given a buy rating to the company’s stock. Bristol-Myers Squibb currently has an average rating of “Hold” and an average price target of $55.88.

In other Bristol-Myers Squibb news, Director Robert J. Bertolini purchased 11,000 shares of the stock in a transaction on Wednesday, July 31st. The stock was acquired at an average cost of $44.72 per share, with a total value of $491,920.00. Following the completion of the purchase, the director now directly owns 11,397 shares of the company’s stock, valued at approximately $509,673.84. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.13% of the company’s stock.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Recommended Story: Average Daily Trade Volume Explained

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.